Finanzwire Finanzwire
Basculer en Français
10336 Companies
214542 Keywords
144368 Articles
113638 Press releases
Headlines Articles Press releases Morphogenesis Inc. Remove
  1. Home
  2. Companies
  3. Morphogenesis Inc.
Finanzwire
Basculer en Français
Headlines Articles Press releases

News

  • BRIEF

    published on 04/25/2024 at 15:05, 2 years ago

    TuHURA Biosciences to Showcase Clinical Trial Results at ASCO 2024

    Clinical Trials Mergers And Acquisitions TuHURA Biosciences Cancer Immunotherapy ASCO 2024
  • PRESS RELEASE

    published on 04/25/2024 at 15:00, 2 years ago

    TuHURA Biosciences to Present Its IFx-2.0 Personalized Cancer Vaccine Clinical Trial Results at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

    TuHURA Biosciences, Inc. announces IFx-2.0 Phase 1b trial results accepted for poster presentation at 2024 ASCO Annual Meeting. Company to form new entity with Kintara Therapeutics, Inc. and focus on cancer vaccines and bi-functional ADCs
    Phase 1b Trial TuHURA Biosciences Inc. IFx-2.0 Poster Presentation Kintara Therapeutics Inc.
    Logo of Morphogenesis Inc.
  • PRESS RELEASE

    published on 12/14/2023 at 16:00, 2 years 4 months ago

    Morphogenesis, Inc. Announces Corporate Rebranding to TuHURA Biosciences, Inc. and Provides a Business Overview

    Logo of Morphogenesis Inc.
  • PRESS RELEASE

    published on 11/08/2023 at 15:00, 2 years 5 months ago

    Morphogenesis, Inc. Biomarker Analysis Data from IFx-Hu2.0 in Melanoma Refractory to Anti-PD1-Based Therapies Demonstrates Ability to Overcome Primary Resistance to Checkpoint Inhibitors and Trigger an Innate Immune Response

    Logo of Morphogenesis Inc.
Accesswire
  • Published on 05/02/2026 at 00:00, 1 hour ago

    Redwood AI Announces Enhanced AI Models, Increasing Evaluated Chemical Reactions Following Preliminary Results from UBC Collaboration

  • Published on 05/02/2026 at 00:00, 1 hour ago

    Onco-Innovations Expands Manufacturing Scale-Up of Its PNKP Inhibitor Technology with Dalton Pharma Services, Advancing Multi-Kilogram Non-GMP Synthesis to Support IND-Enabling Studies

  • Published on 05/01/2026 at 22:30, 2 hours 30 minutes ago

    Nextech3D.ai Appoints New Independent Auditor

  • Published on 05/01/2026 at 22:30, 2 hours 30 minutes ago

    Integrated Rewards Achieves SOC 2 Compliance to Support Enterprise-Scale Growth Across Canada's Card-Linked Rewards Network as EQ Closes Convertible Debt Financing

  • Published on 05/01/2026 at 22:30, 2 hours 30 minutes ago

    Apex Critical Metals Announces Extension of Marketing Agreement with Rumble Strip Media Inc.

View all ACCESSWIRE
EQS Group
  • Published on 05/01/2026 at 19:23, 5 hours 37 minutes ago

    Fuller, Smith & Turner PLC: Transaction in own shares

  • Published on 05/01/2026 at 18:40, 6 hours 20 minutes ago

    Holding(s) in Company

  • Published on 05/01/2026 at 17:47, 7 hours 13 minutes ago

    Key Figures 30.04.2026

  • Published on 05/01/2026 at 17:45, 7 hours 15 minutes ago

    Burkhalter Group acquires Progressio Holding GmbH and anplaq ag, Tamins (GR)

  • Published on 05/01/2026 at 17:21, 7 hours 38 minutes ago

    Fuller, Smith & Turner PLC: Total Voting Rights and Treasury Shares

View all EQS
Les Echos
  • Published on 04/30/2026 at 20:00, 1 day 4 hours ago

    AMA Corp PLC : FY 2025 Earnings & Q1 2026 Revenue

  • Published on 04/30/2026 at 19:16, 1 day 5 hours ago

    AXA announces the results of its Shareholders' Meeting

  • Published on 04/30/2026 at 19:00, 1 day 6 hours ago

    Capital increase through exercise of subscription rights

  • Published on 04/30/2026 at 18:10, 1 day 6 hours ago

    Minutes of the Combined General Meeting held on April 30, 2026

  • Published on 04/30/2026 at 18:00, 1 day 7 hours ago

    TF1 Q1 2026 results - Press release

View all LES ECHOS COMFI WIRE

With finanzwire.com, you can follow all the latest financial news in real time from the best sources for companies listed on the Paris, Brussels, Amsterdam, Lisbon, Frankfurt and New York stock exchanges. You'll have access to summary articles written by us and press releases published by the companies themselves.

Finanzwire

87, rue Ordener - 75018 Paris

Contact us

+33 1 42 23 83 61

© 2026 Finanzwire

Contact Authors Cookies policy Terms and conditions Privacy policy